Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine

Frank Vinluan / medcitynews - FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a common complication of the allogeneic stem cell transplants that are a stan…

AI Summary: Orca Bio’s off‑the‑shelf allogeneic cell therapy received FDA approval, marking a milestone for engineered living medicines. Regulators cleared the product after pivotal efficacy and manufacturing data, offering broader access to cellular therapy but spotlighting cost, supply logistics and the need for robust post‑market safety surveillance.